Tsung-i Hsu

250 Wuxing Street
Taipei, TNQ 11031, Taiwan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 62 publications

KDM1A/HDAC2-driven epigenetic dysregulation maintains a drug-resistant, relapse-initiating glioblastoma cell niche at the peri-tumoral margin.

KDM1A/HDAC2-driven epigenetic dysregulation maintains a drug-resistant, relapse-initiating glioblastoma cell niche at the peri-tumoral margin.

Journal: Biochemical pharmacology

Published: February 23, 2026

Targeting the COX-2/PGE2 axis to enhance NK and T cell immunotherapy in brain tumors.

Targeting the COX-2/PGE2 axis to enhance NK and T cell immunotherapy in brain tumors.

Journal: Cancer immunology, immunotherapy : CII

Published: December 29, 2025

Unmodified γδ T cells exhibit potent antitumor activity in hepatocellular carcinoma and are enhanced by PD-L1 blockade.

Unmodified γδ T cells exhibit potent antitumor activity in hepatocellular carcinoma and are enhanced by PD-L1 blockade.

Journal: Immunobiology

Published: September 16, 2025

Dual suppression of stemness and redox adaptation in glioblastoma through filaggrin upregulation by an abiraterone-based HDAC inhibitor.

Dual suppression of stemness and redox adaptation in glioblastoma through filaggrin upregulation by an abiraterone-based HDAC inhibitor.

Journal: Journal of biomedical science

Published: June 14, 2025

Calanquinone A suppresses glioma progression via STAT3-mediated regulation of c-Myc and MMP9.

Calanquinone A suppresses glioma progression via STAT3-mediated regulation of c-Myc and MMP9.

Journal: Discover oncology

Published: May 23, 2025

Contribution of Prostaglandin E2-Induced Neuronal Excitation to Drug Resistance in Glioblastoma Countered by a Novel Blood-Brain Barrier Crossing Celecoxib Derivative.

Contribution of Prostaglandin E2-Induced Neuronal Excitation to Drug Resistance in Glioblastoma Countered by a Novel Blood-Brain Barrier Crossing Celecoxib Derivative.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: April 08, 2025

Repurposing Linezolid in Conjunction with Histone Deacetylase Inhibitor Access in the Realm of Glioblastoma Therapies.

Repurposing Linezolid in Conjunction with Histone Deacetylase Inhibitor Access in the Realm of Glioblastoma Therapies.

Journal: Journal of medicinal chemistry

Published: January 21, 2025

Progesterone boosts abiraterone-driven target and NK cell therapies against glioblastoma.

Progesterone boosts abiraterone-driven target and NK cell therapies against glioblastoma.

Journal: Journal of experimental & clinical cancer research : CR

Published: July 04, 2024

Potential role of solid lipid curcumin particle (SLCP) as estrogen replacement therapy in mitigating TDP-43-related neuropathy in the mouse model of ALS disease.

Potential role of solid lipid curcumin particle (SLCP) as estrogen replacement therapy in mitigating TDP-43-related neuropathy in the mouse model of ALS disease.

Journal: Experimental neurology

Published: June 04, 2024

Exploring neuron-specific steroid synthesis and DHEAS therapy in Alzheimer's disease.

Exploring neuron-specific steroid synthesis and DHEAS therapy in Alzheimer's disease.

Journal: The Journal of steroid biochemistry and molecular biology

Published: April 03, 2024

First-in-Class Dual EZH2-HSP90 Inhibitor Eliciting Striking Antiglioblastoma Activity In Vitro and In Vivo.

First-in-Class Dual EZH2-HSP90 Inhibitor Eliciting Striking Antiglioblastoma Activity In Vitro and In Vivo.

Journal: Journal of medicinal chemistry

Published: January 29, 2024

Neurocutaneous Melanosis with Meningeal Melanocytosis: A Rare Case of Intracranial Hypertension and Cutaneous Manifestations.

Neurocutaneous Melanosis with Meningeal Melanocytosis: A Rare Case of Intracranial Hypertension and Cutaneous Manifestations.

Journal: Life (Basel, Switzerland)

Published: December 14, 2023

Showing 1-12 of 62

Last Updated: 09/26/2026